Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptors (TCRs) recognizing Cav p peptide–MHC class II complexes are specialized immune receptors that mediate the cellular response to allergens from Cavia porcellus (guinea pig), specifically the major allergen Cav p 1. These TCRs are expressed on the surface of CD4+ T-helper cells and bind to specific peptide fragments of the Cav p 1 protein when they are presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells. This molecular recognition event is a critical step in the development of laboratory animal allergy (LAA) and pet-related asthma, leading to T-cell activation, Th2-polarized cytokine release, and subsequent IgE production. Understanding the structural basis of this interaction is vital for developing targeted immunotherapies, such as peptide-based vaccines or TCR-engineered T-cell modulators, aimed at inducing immune tolerance or desensitization in allergic individuals.
Modulation of T-cell activation through peptide-MHC blockade or induction of T-cell anergy/tolerance via specific immunotherapy.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptors recognizing Cav p peptide–MHC class II complexes (Cav p-TCR).